- Home
- / Mateon Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Mateon Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.3
2021-05-27
Market Capitalization
$6.9 M
2021-05-27
Revenue
$70 K
FY, 2023
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 156.0K | 95.0K | 1.7M | 70.0K | |||||||||||
| General and administrative expense | 5.4M | 4.7M | 4.7M | 5.2M | 4.6M | 5.0M | 3.4M | 2.2M | 2.9M | 5.0M | 5.5M | 4.9M | 573.7K | 376.0K | 3.2M |
| Operating expense total | 10.7M | 8.2M | 8.4M | 12.7M | 13.7M | 13.8M | 13.8M | 3.0M | 4.3M | 9.3M | 5.6M | 376.0K | 3.2M | ||
| EBIT | (11.9M) | (8.1M) | (8.3M) | (12.6M) | (13.7M) | (13.8M) | (13.8M) | (3.0M) | (4.3M) | (7.6M) | (9.1M) | (9.7M) | (6.6M) | (3.6M) | (3.2M) |
| EBIT margin, % | -5174.4% | -8715.8% | -435.7% | ||||||||||||
| Interest income | 7.0K | 12.0K | 4.0K | 6.0K | 27.0K | 106.0K | 35.0K | 16.0K | 123.0 | ||||||
| Interest expense | 3.0M | 1.0M | 365.9K | ||||||||||||
| Pre tax profit | 360.6M | ||||||||||||||
| Income tax expense | 111.6M | ||||||||||||||
| Net Income | (9.7M) | (8.1M) | (8.3M) | (12.6M) | (13.7M) | (13.7M) | (13.8M) | (2.7M) | (6.6M) | (10.0M) | (10.5M) | 4.7M | (8.2M) | (4.8M) | 249.0M |
| EPS | 0.0 | 0.6 |